OKLAHOMA Health Care Authority | Serving Oklahomans through SoonerCare

March 9, 2026

RE: Anticonvulsants, Insomnia Medications, and Semglee® (Insulin Glargine-yfgn) Coverage Changes Effective March 23, 2026

The following changes will take effect on March 23, 2026. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. The Brand Required List can be found on the OHCA website at www.oklahoma.gov/ohca/rx. Pharmacy PA forms can be found on the OHCA website at www.oklahoma.gov/ohca/rxforms.

Anticonvulsants

- **Banzel®** (rufinamide) will no longer be brand preferred but will continue to require PA. Members currently utilizing brand Banzel® will be able to continue its use. New starts will need to use generic rufinamide.
- **Briviact®** (brivaracetam) will be brand preferred and will continue to require PA. Members currently utilizing generic brivaracetam will be able to continue its use. New starts will need to use brand Briviact®.
- **Eprontia®** (topiramate solution) will be brand preferred and will continue to require PA. Members currently utilizing generic topiramate solution will be able to continue its use. New starts will need to use brand Eprontia®.
- **Fycompa®** (perampanel) will be brand preferred and require a PA. Members currently utilizing Fycompa® (brand or generic) will be able to continue its use. New starts will need to use brand Fycompa® in addition to meeting approval criteria.

Insomnia Medications

- **Dalmane®** (flurazepam) will move to the Special PA tier of the Insomnia Medications tier chart. Members currently utilizing flurazepam will need to switch to a lower tiered alternative or a PA request will need to be submitted with patient-specific information.
- **Prosom®** (estazolam) will move to Tier-2 of the Insomnia Medications tier chart. Members currently utilizing estazolam will need to switch to a Tier-1 alternative or a PA request will need to be submitted with patient-specific information.
- **Belsomra®** (suvorexant) will move to Tier-1 of the Insomnia Medications tier chart.

The specific PA requirements for the Anticonvulsants and Insomnia Medications and the Insomnia Medications tier chart can be found on the OHCA website in the “Central Nervous System/Behavioral Health” therapeutic category.

Semglee® (Insulin Glargine-yfgn)

- **Semglee®** (insulin glargine-yfgn) pens and vials will be co-preferred (brand or generic) and will be available without PA, in addition to Lantus® (insulin glargine).

Thank you for the services you provide to Oklahomans insured by SoonerCare!